Analysis of the EF-14 phase III trial reveals that tumor treating fields alter progression patterns in glioblastoma.

person Suriya A. Jeyapalan Rhode Island Hospital, Brown University, Newton, MA info_outline Suriya A. Jeyapalan, Steven A Toms, Andreas Felix Hottinger, Lawrence Kleinberg, Erqi Pollom, Scott G. Soltys, Martin Glas

Authors person Suriya A. Jeyapalan Rhode Island Hospital, Brown University, Newton, MA info_outline Suriya A. Jeyapalan, Steven A Toms, Andreas Felix Hottinger, Lawrence Kleinberg, Erqi Pollom, Scott G. Soltys, Martin Glas Organizations Rhode Island Hospital, Brown University, Newton, MA, Warren Alpert Medical School of Brown University, Providence, RI, CHUV University Hospital, Lausanne, Switzerland, Johns Hopkins University School of Medicine, Baltimore, MD, Stanford University Cancer Center, Stanford, CA, Stanford Cancer Institute, Palo Alto, CA, University Hospital Essen, Essen, Germany Abstract Disclosures Research Funding Pharmaceutical/Biotech Company Background: The EF-14 [NCT00916409] trial showed that addition of alternating electric fields (Tumor Treating Fields, TTFields) to Temozolomide (TMZ) resulted in improved survival in newly diagnosed Glioblastoma (GBM) patients with supratentorial tumors treated compared to TMZ alone. TTFields delivery is planned to optimize dose at the tumor bed, leading to the hypothesis that TTFields treated patients are more likely to exhibit distal progressions, including progression to the infratentorial brain where TTFields dose is minimal when targeting the supratentorium. Here we present analysis of the EF-14 trial testing this hypothesis. Methods: Patients on treatment for more than two months who had an MRI that exhibited progression were included in the study (treatment: N=280/466, control: N=122/229). Regions of enhancing tumor, necrosis and resection were contoured on T1 contrast MRIs acquired at baseline and at the date of first progression. New lesions at progression were classified as distal if they appeared outside of a Proximal Boundary Zone (PBZ) of 20 mm surrounding the lesions identified in the baseline MRI. The rate of occurrence of distal progressions in the TTFields-treated arm was compared to the rate observed in the control arm. Patients with (distal) infratentorial progression were identified. Results: Distal progressions were more common in the treatment arm (49/280 (18%) vs. 10/122 (8%) P<0.02; chi-squared). Infratentorial progression were observed in 4% (10 patients) of the treatment arm vs. 0 patients in the control (P<0.002 t-test). Distal lesions at progression were more distant from the original lesion in the TTFields treated arm (58.57 + 28.12 mm vs 46.61 + 20.48 mm, P<0.02; Wilcoxon rank sum test. The relative tumor growth rates in TTFields treated patients were significantly slower than those observed in the control arm (0.036+ 0.126 ml/day vs. 0.036+ 0.183 ml/day P<0.03; t-test). Conclusions: This analysis indicates that adding TTFields to TMZ could impact GBM growth patterns. The results suggest that TTFields increases local control of tumor growth, emphasizing the need for adaptive treatment after progression to control progressing disease. Clinical trial information: NCT00916409